CN103561747B - 靶向治疗额颞叶变性的方法 - Google Patents

靶向治疗额颞叶变性的方法 Download PDF

Info

Publication number
CN103561747B
CN103561747B CN201280025073.5A CN201280025073A CN103561747B CN 103561747 B CN103561747 B CN 103561747B CN 201280025073 A CN201280025073 A CN 201280025073A CN 103561747 B CN103561747 B CN 103561747B
Authority
CN
China
Prior art keywords
alkyl
aryl
heterocyclyl
heteroaryl
ftld
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280025073.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103561747A (zh
Inventor
H.帕茨克
G.凯尼格
J-F.布莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forum Pharmaceuticals Inc
Original Assignee
Forum Pharmaceuticals Inc
EnVivo Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forum Pharmaceuticals Inc, EnVivo Phamaceuticals Inc filed Critical Forum Pharmaceuticals Inc
Publication of CN103561747A publication Critical patent/CN103561747A/zh
Application granted granted Critical
Publication of CN103561747B publication Critical patent/CN103561747B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201280025073.5A 2011-03-26 2012-03-26 靶向治疗额颞叶变性的方法 Expired - Fee Related CN103561747B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467989P 2011-03-26 2011-03-26
US61/467,989 2011-03-26
PCT/US2012/030527 WO2012135097A1 (en) 2011-03-26 2012-03-26 Methods of targeted treatment of frontotemporal lobar degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610143729.3A Division CN105748484A (zh) 2011-03-26 2012-03-26 靶向治疗额颞叶变性的方法

Publications (2)

Publication Number Publication Date
CN103561747A CN103561747A (zh) 2014-02-05
CN103561747B true CN103561747B (zh) 2016-04-06

Family

ID=45931040

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280025073.5A Expired - Fee Related CN103561747B (zh) 2011-03-26 2012-03-26 靶向治疗额颞叶变性的方法
CN201610143729.3A Pending CN105748484A (zh) 2011-03-26 2012-03-26 靶向治疗额颞叶变性的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610143729.3A Pending CN105748484A (zh) 2011-03-26 2012-03-26 靶向治疗额颞叶变性的方法

Country Status (13)

Country Link
US (1) US20140179678A1 (https=)
EP (1) EP2691099A1 (https=)
JP (2) JP5995956B2 (https=)
CN (2) CN103561747B (https=)
AR (1) AR085572A1 (https=)
AU (1) AU2012236852A1 (https=)
CA (1) CA2831291A1 (https=)
IL (1) IL228405A0 (https=)
MX (1) MX2013011096A (https=)
RU (1) RU2013147810A (https=)
TW (1) TW201247205A (https=)
UY (1) UY33973A (https=)
WO (1) WO2012135097A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149836B2 (en) 2014-03-21 2018-12-11 The Board Of Regents Of The University Of Texas System Isoxazole treatments for frontotemporal dementia
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
AR119149A1 (es) * 2019-06-12 2021-11-24 Arkuda Therapeutics Derivados de isoquinolina como moduladores de la progranulina
US20230201269A1 (en) * 2020-04-24 2023-06-29 Spinalcyte, Llc Treatment of frontotemporal dementia using fibroblasts and products thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573333A (zh) * 2006-10-28 2009-11-04 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2009137499A1 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
WO2009137462A2 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
US20090291444A1 (en) * 2008-03-31 2009-11-26 Jason Eriksen Methods and materials for detecting and treating dementia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573333A (zh) * 2006-10-28 2009-11-04 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US20090291444A1 (en) * 2008-03-31 2009-11-26 Jason Eriksen Methods and materials for detecting and treating dementia
WO2009137499A1 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
WO2009137462A2 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Suberoylanilide Hydroxamic Acid (Vorinostat) Up-regulates Progranulin Transcription;Basar Cenik等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20110323;第286卷(第18期);第16101-16108页 *

Also Published As

Publication number Publication date
TW201247205A (en) 2012-12-01
JP2014511848A (ja) 2014-05-19
CN103561747A (zh) 2014-02-05
IL228405A0 (en) 2013-12-31
JP5995956B2 (ja) 2016-09-21
EP2691099A1 (en) 2014-02-05
CN105748484A (zh) 2016-07-13
CA2831291A1 (en) 2012-10-04
RU2013147810A (ru) 2015-05-10
US20140179678A1 (en) 2014-06-26
AU2012236852A1 (en) 2013-09-26
MX2013011096A (es) 2014-06-06
WO2012135097A1 (en) 2012-10-04
AR085572A1 (es) 2013-10-09
JP2017019826A (ja) 2017-01-26
UY33973A (es) 2012-10-31
NZ615177A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
CN101573333B (zh) 组蛋白脱乙酰酶抑制剂
RU2535667C2 (ru) Энантиомеры спиро-оксиндольных соединений и их применение в качестве терапевтических средств
WO2009033281A1 (en) Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer
RS52852B (sr) Sredstva za prevenciju i lečenje poremećaja koji obuhvataju modulaciju ryr receptora
EA021240B1 (ru) Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace)
WO2012033956A1 (en) Cognition enhancing compounds and compositions, methods of making, and methods of treating
WO2014052836A2 (en) Methods and compositions for treating infection
CA2919952A1 (en) Methods of treating muscular dystrophy
EP3439665B1 (en) Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists
CN103561747B (zh) 靶向治疗额颞叶变性的方法
US20230257410A1 (en) Phenothiazine derivatives and uses thereof
US20160207893A1 (en) Novel calcium modulators
WO2018213491A1 (en) Methods of treating epilepsy and neurodevelopmental disorders
CN106687115B (zh) 预防和/或治疗尿失禁的药物组合物
WO2009120700A2 (en) Inhibition of dcps
US9598434B2 (en) Benzazepine compound
CN115515682B (zh) 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
CN105579100A (zh) 多发性骨髓瘤的治疗
WO2021160012A1 (zh) 一种特异性降解tau蛋白的小分子化合物及其用途
EP2373316A1 (en) Treatment for glomerulonephritis with 2 - ý 4- ( -7-ethyl-5h-pyrrolo ý 2,3-b¨-pyrazin- 6 -yl) propan-2-ol
NZ615177B2 (en) Methods of targeted treatment of frontotemporal lobar degeneration
CN118354770A (zh) 具有gabaa受体活性的类黄酮衍生物及使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: FORUM PHARMACEUTICALS INC.

Address before: Massachusetts, USA

Applicant before: En Vivo Pharmaceuticals Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: EN VIVO PHARMACEUTICALS INC. TO: FULAMU PHARMACEUTICAL CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160406

Termination date: 20180326

CF01 Termination of patent right due to non-payment of annual fee